DGAP-News: Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-lgE Vaccine
(firmenpresse) - EquityStory AG-News: Cytos Biotechnology AG / Key word(s): Research
Update
Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-lgE
Vaccine
04.02.2013 / 07:00
---------------------------------------------------------------------
Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-lgE
Vaccine
Schlieren (Zurich), Switzerland, February 4th , 2013 - Cytos Biotechnology
Ltd (SIX:CYTN) has been informed by Pfizer Inc. that the first patient has
been dosed in a Phase 1 clinical trial with an anti-IgE vaccine, which is
being developed under a license agreement between both parties. Pfizer's
anti-IgE vaccine is based on Cytos' VLP ('virus-like-particle') vaccine
platform.
Christian Itin, Chairman and Chief Executive Officer of Cytos, comments:
'We are very pleased that Pfizer has advanced its anti-IgE vaccine to a
Phase 1 clinical trial. This is an important milestone for the program and
provides further evidence of the potential of Cytos' B-cell vaccine
platform based on Q beta-derived virus like particles.'
Pfizer acquired world-wide exclusive rights to develop, manufacture and
commercialize certain specified vaccines based on Cytos' VLP platform in
2009.
###
For further information, please contact:
Cytos Biotechnology Ltd
Harry Welten
Chief Financial Officer
Tel: +41 44 733 46 46
e-mail: harry.welten(at)cytos.com
US Investor enquiries
Susan A. Noonan
Tel: +1 (212) 966 3650
e-mail: susan(at)sanoonan.com
About Cytos Biotechnology Ltd
Cytos is a public biopharmaceutical company focused on the development of
targeted immuno-therapies. The Company's lead product candidate CYT003 is a
first-in-class biologic in Phase 2 clinical development as a potential new
treatment for allergic asthma.
CYT003 acts via a novel, allergen-independent mechanism of action to
selectively suppress the body's immune response to allergens, a predominant
risk factor for asthma. In a successfully completed Phase 2a study, CYT003
was shown to maintain asthma control and lung function and asthma control
in patients with persistent allergic asthma, even as standard inhaled
corticosteroid treatment was withdrawn. CYT003 has been shown to be safe in
over 450 patients to date.
Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of
Technology (ETH) in Zurich. It is located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.
www.cytos.com
This foregoing press release may contain forward-looking statements that
include words or phrases such as 'are intended for', 'are designed to', or
other similar expressions. These forward-looking statements are subject to
a variety of significant uncertainties, including scientific, business,
economic and financial factors, and therefore actual results may differ
significantly from those presented. There can be no assurance that any
further therapeutic entities will enter clinical trials, that clinical
trial results will be predictive for future results, that therapeutic
entities will be the subject of filings for regulatory approval, that any
drug candidates will receive marketing approval from the U.S. Food and Drug
Administration or equivalent regulatory authorities, or that drugs will be
marketed successfully. Against the background of these uncertainties
readers should not rely on forward-looking statements. TheCompany assumes
no responsibility to update forward-looking statements or adapt them to
future events or developments.
End of Corporate News
---------------------------------------------------------------------
04.02.2013 This press release was distributed by EQS CORPORATE
COMMUNICATIONS.
www.eqs.com - news archive: www.eqs.com/ch/presskit
The issuer is responsible for the contents of the release.
---------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Switzerland
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info(at)cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Freiverkehr in Berlin, München, Stuttgart;
Open Market in Frankfurt; SIX
End of News EquityStory AG News-Service
---------------------------------------------------------------------
200410 04.02.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.02.2013 - 07:00 Uhr
Sprache: Deutsch
News-ID 225642
Anzahl Zeichen: 12246
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 258 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-lgE Vaccine"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytos Biotechnology AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
